Cerebrolysin
Neurotrophic peptide mix
Mixture of peptides derived from porcine brain tissue. Not FDA-approved; approved in some countries outside the US.
Synthetic angiotensin IV analog. Not FDA-approved; evidence is preclinical.
Dihexa (also called PNB-0408) is a synthetic six-carbon angiotensin IV analog with structural modifications intended to confer oral bioavailability and CNS penetration. It was developed at Washington State University by Joseph Harding and colleagues based on research into angiotensin IV signaling in the hippocampus and other brain regions. Dihexa is not FDA-approved for any use in the United States.
The compound has been promoted in some circles as a cognitive enhancer based on preclinical research in animal models. These claims have substantially outpaced the available evidence, as human data are essentially absent.
Proposed mechanisms come from laboratory and animal research:
Human clinical trial evidence on Dihexa is essentially absent. The compound has been characterized in preclinical studies but has not progressed to substantial human clinical research. Well-controlled human trials establishing its effectiveness and safety are lacking.
The Tide does not prescribe Dihexa:
Dihexa remains an experimental research compound.
Human safety data are essentially absent, and long-term effects are unknown. There are theoretical concerns about HGF signaling in cancer contexts, since HGF/c-Met signaling supports some malignancies. Products sold outside regulated channels (e.g., “research peptides”) may vary in purity, dose, and sterility.
Neurotrophic peptide mix
Mixture of peptides derived from porcine brain tissue. Not FDA-approved; approved in some countries outside the US.
NA-Semax-Amidate
Chemically modified analog of Semax. Not FDA-approved; investigational.
NA-Selank-Amidate
Chemically modified analog of Selank. Not FDA-approved; investigational.